Overview
Emmanuelle Trombe, Laetitia de Dinechin and Shurong Qu advised a clinical-stage biotechnology company in an asset transfer, licensing and co-development agreement for its flagship drug candidate with a Chinese pharmaceutical group for more than EUR 60 million.
